| Bioactivity | Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia[1]. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion[2]. |
| Target | Thrombin |
| Name | Melagatran |
| CAS | 159776-70-2 |
| Formula | C22H31N5O4 |
| Molar Mass | 429.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eriksson M, et al. Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. Expert Opin Investig Drugs. 2000 May;9(5):1129-37. [2]. Mehta JL, et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol. 1998 Mar;31(3):345-51. |
Melagatran
CAS: 159776-70-2 F: C22H31N5O4 W: 429.51
Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagul
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.